Silexion Therapeutics has partnered with global therapeutics company Catalent to advance its breakthrough RNAi therapy SIL204, targeting multiple KRAS mutations in pancreatic cancer. The collaboration will leverage Catalent's Limoges, France facility to optimize systemic and intratumoral delivery formulations, positioning the therapy for potential clinical trials in the first half of 2026.
The partnership represents a significant milestone in precision oncology, addressing a critical challenge in cancer treatment. SIL204 has demonstrated remarkable preclinical efficacy, including 70-80% tumor reduction across multiple pancreatic cancer models and, notably, the ability to reduce metastatic spread to secondary organs.
Unlike existing therapies that target specific KRAS mutations, Silexion's approach can potentially silence multiple mutations at the genetic level. This is particularly significant given that KRAS mutations are present in over 90% of pancreatic cancers, with current treatments addressing only 1-2% of cases.
The collaboration occurs within a rapidly expanding precision medicine market projected to grow from $102 billion in 2024 to $470 billion by 2034. For pancreatic cancer patients, where five-year survival rates remain below 13%, this innovative approach could represent a transformative advancement in treatment options.
Silexion's dual-route strategy—integrating systemic and intratumoral delivery—distinguishes its approach from existing therapies. The company's ability to maintain therapeutic levels for over 56 days from a single administration further underscores the potential of its RNAi technology.
With Wall Street analysts maintaining a bullish outlook and a potential 500% price target, Silexion stands at the forefront of a promising development in oncological research. The partnership with Catalent significantly enhances the company's credibility and trajectory toward clinical trials.
